Malaria DNA vaccine - University of Oxford

Drug Profile

Malaria DNA vaccine - University of Oxford

Latest Information Update: 09 Sep 2015

Price : $50

At a glance

  • Originator University of Oxford
  • Developer Oxxon Therapeutics; Pfizer; University of Oxford
  • Class Antimalarials; DNA vaccines; Gene therapies; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 16 Dec 2003 A phase IIb trial has been completed for Malaria in Gambia
  • 09 Dec 2003 A clinical study has been added to the Parasitic Infections immunogenicity section
  • 03 Dec 2003 Phase-II clinical trials in Malaria in Gambia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top